Cipla

Mumbai, India Founded: 1935 • Age: 91 yrs Listed Fortune India 500 · #100 India's Most Valuable
APIs, generic drugs, and formulation services are manufactured.
Request Access
Report Incorrect Data
Page last updated

About Cipla

Cipla is a publicly listed company based in Mumbai (India) founded in 1935. APIs, generic drugs, and formulation services are manufactured. The company has 2,319 employees. Cipla has completed 9 acquisitions, including Avenue Therapeutics, Cipla Biotec and Cipla Medpro. Its chief executive, as recorded, is Umang Vohra. Its website cipla.com draws about 201 thousand monthly visits. Its Indian entity Cipla Limited reported revenue of ₹20,103 Cr. Cipla offers products and services including Potatoes and Grain Marketing. Its focus areas include Traditional Pharmaceuticals and Diversified.

Company details

Founded in 1935 and headquartered in Mumbai, India, Cipla operates in the pharmaceutical sector. Active pharmaceutical ingredients, generic drugs, and formulation development services are produced. A broad portfolio covers therapeutic areas including allergy, cardiology, dermatology, diabetology, gastroenterology, HIV-AIDS, oncology, respiratory, and urology. Leadership is provided by CEO and Managing Director Umang Vohra. Operations focus on global distribution of these products.

Cipla is ranked #100 on the Fortune India 500 (2025).

Recognitions & Rankings of Cipla

Fortune India 500 2025 edition
Rank#100
Total income
₹28,742 Cr
Profit
₹5,273 Cr
Last year #92
India's Most Valuable Companies 2025 edition · Source: Hurun India
2024 #47 2023 #39 2022 #43
  • Headquarters Mumbai, India
  • Employees 2,319
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website cipla.com
  • Social LinkedIn X Facebook
  • Legal Name Cipla Ltd
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹1,14,712 Cr

    CIPLA · NSE

  • Share Price
    ₹1,408.30

    -0.82% today

  • Revenue
    ₹39,012 Cr

    FY 2025-26 · +5.3% YoY

  • EBITDA
    ₹5,607 Cr

    Margin 14.4%

  • Net Profit
    ₹3,806 Cr

    FY 2025-26 · -26.0% YoY

  • P/E (TTM)
    36.5x

    P/B 3.2x

  • ROE
    11.8%

    ROCE 15.7%

  • Debt / Equity
    0.02

    Interest cover 1.2x

  • Employee Count
    2,319
  • Investments & Acquisitions
    Avenue Therapeutics

    & 8 more

Products & Services of Cipla

Cipla offers a comprehensive portfolio of products and services, including Potatoes and Grain Marketing.

Potatoes
Agricultural Products

Potatoes are farmed and sold for food and industrial uses by the company

Grain Marketing
Marketing Services

Grains are promoted and distributed from farms by the company

Board of directors of Cipla Limited (Cipla)

Cipla Limited is the primary company behind Cipla. The board of Cipla Limited currently have 10 directors; the longest-serving is Yusuf Khwaja Hamied, appointed in 1972. 32 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Yusuf Khwaja Hamied
DIN 00029049
Director21 Jul 197254 yrs 3 moCipla Limited
Adil Zainulbhai
DIN 06646490
Director23 Jul 201412 yrs 3 moCipla Limited
Prathivadibhayankara Rajagopalan Ramesh
DIN 01915274
Director01 Jul 20215 yrs 4 moCipla Limited
Mandar Purushottam Vaidya
DIN 09690327
Director29 Jul 20224 yrs 3 moCipla Limited
Balram Bhargava
DIN 10479707
Director01 Apr 20242 yrs 7 moCipla Limited
Sharmila Nitin Paranjpe
DIN 02328770
Director01 Sep 20242 yrs 2 moCipla Limited
Abhijit Jagdish Joshi
DIN 07115673
Director03 Sep 20242 yrs 2 moCipla Limited
Kamil Hamied
DIN 00024292
Director01 Nov 20242 yrsCipla Limited
Maya Hari
DIN 01123969
Director01 Nov 20242 yrsCipla Limited
Achin Gupta
DIN 09491674
Managing Director01 Apr 20267 moCipla Limited

People of Cipla

406 people are tracked at Cipla (171 in leadership, 8 in board & advisors, 227 in team); the tracked headcount is 2,319.

NameRoleGroup
Umang Vohra
CEO & Managing DirectorLeadership
Rahul Verma
Vice President Corporate FinanceLeadership
Nirav Dave
Sectional Head Civil EngineeringLeadership
Urvi Ashar
Associate Director Human ResourcesLeadership
Johann Bloem
Head - Market Access And PMO AfricaLeadership
Prasad Deshmukh
Vice PresidentLeadership
Vinay Patil
DirectorLeadership
Premchand Yadav
Associate Director MarketingLeadership
Deepali Choudhary
Director & Cluster Finance HeadLeadership
Rohan Parmar
Senior Manager- Block Head OperationsLeadership
Sanjeev Asgekar
Head Quality Operations -formulationsLeadership
Siddharth Agrawal
Associate Director ( Formulation Development)Leadership
Mahesh Namdev
Associate Director - Marketing HeadLeadership
Rajamani Sethuraman
Senior DirectorLeadership
Dinesh Jain
Executive Vice President, Head - Corporate FinanceLeadership
Dr Sandesh Sawant
Head-clinical TrialsLeadership
Hemanth Panasa
Vice President - Centre Of Excellence (coe), Sterile Quality OperationsLeadership
Kailash Nale
Head of Quality Operations -One AfricaLeadership
Mandeep Warrier
BU HeadLeadership
Vijendra Singh Solanki
Director & National Sales HeadLeadership

386 more people are available in the full profile.

Premium access

Complete people profiles for Cipla

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Cipla

Cipla is a publicly listed company on the NSE with ticker symbol CIPLA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date08 Feb 1995
  • Listed onNSE: CIPLA
  • Listed entityCipla Ltd
  • Exchange sectorHealth technology
  • ISININE059A01026
  • Share price₹1,314.60 (-1.13% on the day) · 2026-10-14
  • Market capitalisation₹107,447 Cr
  • Price to earnings31.5
  • EPS (diluted, trailing year)₹41.70
  • Dividend yield0.98%
  • Volume (last session)993,972

Financials of Cipla

Exchange-reported figures of Cipla Limited, the listed company behind Cipla (NSE: CIPLA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹39,012 Cr
+5.3% YoY
EBITDA
₹5,607 Cr
-21.3% YoY
Profit After Tax
₹3,806 Cr
-26.0% YoY
Net Worth
₹34,432 Cr
+10.4% YoY
Total Assets
₹35,561 Cr
+11.0% YoY
Total Debt
₹614 Cr
+40.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue39,01237,03935,41530,93829,71928,22717,132
Revenue growth+5.3%+4.6%+14.5%+4.1%+5.3%+64.8%-
EBITDA5,6077,1286,0964,8454,3714,2523,206
EBITDA margin+14.4%+19.2%+17.2%+15.7%+14.7%+15.1%+18.7%
Profit before tax5,2246,8215,7024,0383,4933,2902,178
Net profit3,8065,1464,2072,8422,5822,3691,458
Net profit margin+9.8%+13.9%+11.9%+9.2%+8.7%+8.4%+8.5%
EPS (₹)48.0265.2951.0534.7131.1929.8219.18
Balance sheet
Total assets35,56132,03527,62124,78522,42520,87819,351
Net worth34,43231,19326,70623,40820,84218,32715,763
Total debt6144385598031,0562,0142,816
Cash & bank1,3078008751,5651,9281,4011,004
Net working capital9,68510,6589,6749,2008,0846,9466,744
Cash flow
Cash from operations3,9405,0054,1343,2383,3263,7553,068
Cash from investing(2,234)(3,682)(2,982)(2,376)(1,858)(2,374)114
Cash from financing(1,234)(1,293)(1,200)(958)(1,600)(1,240)(2,949)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue7,4047,1196,5417,0747,5896,9576,7307,073
Revenue growth (YoY)-2.4%+2.3%-2.8%+0.0%+7.6%+3.9%--
Other income151211148206269259289222
EBITDA1,3881,1929559791,8951,7781,5381,989
EBITDA margin+18.8%+16.8%+14.8%+14.1%+25.4%+26.0%+23.3%+28.6%
Depreciation345304383278297253309280
Interest16.7417.0313.1314.0313.1814.0514.0214.64
Profit before tax1,1771,0827078931,8541,7701,5041,916
Tax321295157219500478279332
Net profit8577875506751,3531,2921,2251,584
EPS (₹)10.859.766.868.3616.7216.0615.1219.43
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20,06519,95217,48315,05815,38111,30312,659
Revenue growth+0.6%+14.1%+16.1%-2.1%+36.1%-10.7%-
EBITDA4,1915,7784,4843,1673,7113,0672,707
EBITDA margin+20.9%+29.0%+25.7%+21.0%+24.1%+27.1%+21.4%
Profit before tax4,6366,4695,3103,3753,8803,2082,964
Net profit3,4424,8134,0382,5552,9092,4292,227
Net profit margin+17.2%+24.1%+23.1%+17.0%+18.9%+21.5%+17.6%
EPS (₹)43.5263.8650.5031.1436.6630.6128.75
Balance sheet
Total assets34,66732,41428,17424,87522,71820,19017,679
Net worth34,20132,09927,97424,63822,51419,92817,403
Total debt12511745.5550.0923.4552.126.06
Cash & bank5192783339661,428875523
Net working capital7,3188,3687,6287,9156,6455,5185,579
Cash flow
Cash from operations2,8323,3013,7273,0352,7733,4602,018
Cash from investing(1,344)(2,309)(2,883)(2,758)(2,464)(3,361)(1,127)
Cash from financing(1,322)(1,074)(709)(425)(427)(65.80)(694)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5,0675,0784,2104,4985,2265,0464,7984,971
Revenue growth (YoY)-3.0%+0.6%-12.3%-9.5%+9.4%+12.1%--
Other income148243180417255271588189
Total expenses3,9573,9923,6434,0213,7033,4223,4793,309
EBITDA1,1101,0865674771,5231,6241,3191,662
EBITDA margin+24.5%+23.2%+14.8%+11.2%+33.9%+36.1%+31.0%+40.2%
Depreciation189169218153141146148143
Interest5.925.686.744.032.655.883.493.55
Profit before tax1,0621,1545227361,6331,7441,7561,704
Tax275291138119423441270266

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 13 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue7,4047,1196,5417,0747,5896,9576,7307,073
Revenue growth (YoY)-2.4%+2.3%-2.8%+0.0%+7.6%+3.9%--
Other income151211148206269259289222
EBITDA1,3881,1929559791,8951,7781,5381,989
EBITDA margin+18.8%+16.8%+14.8%+14.1%+25.4%+26.0%+23.3%+28.6%
Depreciation345304383278297253309280
Interest16.7417.0313.1314.0313.1814.0514.0214.64
Profit before tax1,1771,0827078931,8541,7701,5041,916
Tax321295157219500478279332
Net profit8577875506751,3531,2921,2251,584
EPS (₹)10.859.766.868.3616.7216.0615.1219.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue39,01237,03935,41530,93829,71928,22717,132
Revenue growth+5.3%+4.6%+14.5%+4.1%+5.3%+64.8%-
Other income882862747475281266344
Total expenses33,40529,91129,31926,09325,34923,97513,926
Employee cost5,3664,8334,3103,8303,5303,2523,027
EBITDA5,6077,1286,0964,8454,3714,2523,206
EBITDA margin+14.4%+19.2%+17.2%+15.7%+14.7%+15.1%+18.7%
Depreciation1,2111,1071,0511,1721,0521,0681,175
Interest54.3962.0189.88110106161197
Profit before tax5,2246,8215,7024,0383,4933,2902,178
Tax1,3541,5301,5471,203934889631
Net profit3,8065,1464,2072,8422,5822,3691,458
Net profit margin+9.8%+13.9%+11.9%+9.2%+8.7%+8.4%+8.5%
EPS (₹)48.0265.2951.0534.7131.1929.8219.18
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital162162161161161161161
Reserves & surplus34,27031,03226,54523,24620,68018,16515,602
Shareholders' funds (net worth)34,43231,19326,70623,40820,84218,32715,763
Minority interest88.2995.8095.90306276259294
Secured loans0.0011.9891.77429376392423
Unsecured loans6144264683746801,6222,393
Total debt6144385598031,0562,0142,816
Total liabilities35,56132,03527,62124,78522,42520,87819,351
Assets
Gross block23,42219,55318,14617,12216,96815,78715,151
Net block12,43410,0069,6079,1609,6839,5169,683
Capital work in progress2,0421,5661,1531,093766969825
Investments8,2237,9335,4493,6622,5512,7101,471
Inventories6,5975,6425,2385,1565,3504,6694,378
Sundry debtors5,6205,5064,7714,0573,4243,4463,891
Cash & bank balances1,3078008751,5651,9281,4011,004
Loans & advances2,9424,0073,7022,9371,8131,4071,417
Total current assets16,46615,95614,58513,71512,51610,92310,690
Total current liabilities6,7825,2984,9124,5154,4323,9773,946
Net working capital9,68510,6589,6749,2008,0846,9466,744
Total assets35,56132,03527,62124,78522,42520,87819,351
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash543512561658790649508
Net cash from operating activities3,9405,0054,1343,2383,3263,7553,068
Net cash from investing activities(2,234)(3,682)(2,982)(2,376)(1,858)(2,374)114
Net cash from financing activities(1,234)(1,293)(1,200)(958)(1,600)(1,240)(2,949)
Net change in cash47330.31(48.99)(96.78)(132)141234
Closing cash1,3078008751,5651,9281,4011,004
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.3%+4.6%+14.5%+4.1%+5.3%+64.8%-
EBITDA growth-21.3%+16.9%+25.8%+10.8%+2.8%+32.6%-
PBT growth-23.4%+19.6%+41.2%+15.6%+6.2%+51.1%+4.8%
Net income growth-26.0%+22.3%+48.0%+10.1%+9.0%+62.5%-
Revenue CAGR (3Y)+8.0%+7.6%+7.9%+21.8%+22.0%+23.0%+6.0%
EBITDA CAGR (3Y)+5.0%+17.7%+12.8%+14.8%+12.2%+15.7%+9.0%
Profitability & leverage
Net income margin+9.9%+14.3%+11.7%+9.2%+8.6%+8.5%+9.0%
Return on capital employed+15.7%+23.2%+22.3%+17.8%+16.8%+17.4%+12.2%
Return on net worth+11.8%+18.3%+16.6%+12.8%+13.1%+14.1%+10.1%
Debt / equity0.020.020.030.040.080.140.23
Long-term debt / equity0.010.010.010.020.050.110.20
Interest cover1.241.031.782.983.205.059.72
Efficiency & per share
Fixed asset turnover1.821.962.011.821.811.821.18
Inventory turnover6.386.816.815.895.936.244.11
Debtors turnover7.017.218.028.278.657.694.26
EPS (₹)48.0265.2951.0534.7131.1929.8219.18
Dividend per share (₹)13.0016.0013.008.505.005.004.00
Book value per share (₹)426.24386.25330.79290.01258.33227.25195.51
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue5,0675,0784,2104,4985,2265,0464,7984,971
Revenue growth (YoY)-3.0%+0.6%-12.3%-9.5%+9.4%+12.1%--
Other income148243180417255271588189
Total expenses3,9573,9923,6434,0213,7033,4223,4793,309
EBITDA1,1101,0865674771,5231,6241,3191,662
EBITDA margin+24.5%+23.2%+14.8%+11.2%+33.9%+36.1%+31.0%+40.2%
Depreciation189169218153141146148143
Interest5.925.686.744.032.655.883.493.55
Profit before tax1,0621,1545227361,6331,7441,7561,704
Tax275291138119423441270266
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20,06519,95217,48315,05815,38111,30312,659
Revenue growth+0.6%+14.1%+16.1%-2.1%+36.1%-10.7%-
Other income1,1231,2791,434826742654893
Total expenses15,87414,17412,99911,89111,6708,2359,952
Employee cost3,3503,0552,6892,3812,1221,7041,911
EBITDA4,1915,7784,4843,1673,7113,0672,707
EBITDA margin+20.9%+29.0%+25.7%+21.0%+24.1%+27.1%+21.4%
Depreciation658574588596547469600
Interest19.3015.1120.2522.2726.9345.0736.05
Profit before tax4,6366,4695,3103,3753,8803,2082,964
Tax1,1211,3111,233862922739646
Net profit3,4424,8134,0382,5552,9092,4292,227
Net profit margin+17.2%+24.1%+23.1%+17.0%+18.9%+21.5%+17.6%
EPS (₹)43.5263.8650.5031.1436.6630.6128.75
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital162162161161161161161
Reserves & surplus34,04031,93827,81224,47722,35219,76617,242
Shareholders' funds (net worth)34,20132,09927,97424,63822,51419,92817,403
Secured loans0.000.000.000.000.000.000.00
Unsecured loans12511745.5550.0923.4552.126.06
Total debt12511745.5550.0923.4552.126.06
Total liabilities34,66732,41428,17424,87522,71820,19017,679
Assets
Gross block10,5008,6708,0467,7667,3887,0666,698
Net block5,1943,8783,7193,8093,9104,0664,151
Capital work in progress978638670504268355320
Investments17,61617,35113,79411,90910,9749,7267,190
Inventories4,3543,6073,2543,2773,4863,0863,021
Sundry debtors3,3973,8602,6822,8882,7943,0353,560
Cash & bank balances5192783339661,428875523
Loans & advances2,8753,7744,2053,4671,5881,1911,088
Total current assets11,14411,52010,47410,6009,2968,1878,193
Total current liabilities3,8263,1522,8462,6852,6512,6692,613
Net working capital7,3188,3687,6287,9156,6455,5185,579
Total assets34,66732,41428,17424,87522,71820,19017,679
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash82.7416529.4817729526264.47
Net cash from operating activities2,8323,3013,7273,0352,7733,4602,018
Net cash from investing activities(1,344)(2,309)(2,883)(2,758)(2,464)(3,361)(1,127)
Net cash from financing activities(1,322)(1,074)(709)(425)(427)(65.80)(694)
Net change in cash166(81.78)135(148)(117)33.18197
Closing cash5192783339661,428875523
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+0.6%+14.1%+16.1%-2.1%+36.1%-10.7%-
EBITDA growth-27.5%+28.9%+41.6%-14.7%+21.0%+13.3%-
PBT growth-28.3%+21.8%+57.3%-13.0%+21.0%+8.2%+18.9%
Net income growth-28.5%+19.2%+58.0%-12.2%+19.8%+9.1%-
Revenue CAGR (3Y)+10.0%+9.1%+15.7%+6.0%+7.5%-0.3%+5.5%
EBITDA CAGR (3Y)+9.8%+15.9%+13.5%+5.4%+14.1%+13.1%+19.3%
Profitability & leverage
Net income margin+17.5%+25.9%+23.3%+16.7%+19.2%+21.8%+18.3%
Return on capital employed+13.9%+21.4%+20.1%+14.3%+18.2%+14.7%+17.8%
Return on net worth+10.6%+17.2%+15.5%+10.7%+13.9%+13.0%+14.0%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.550.290.520.870.851.731.71
Efficiency & per share
Fixed asset turnover2.092.392.211.992.131.641.97
Inventory turnover5.045.825.354.454.683.704.30
Debtors turnover5.536.106.285.305.283.433.76
EPS (₹)43.5263.8650.5031.1436.6630.6128.75
Dividend per share (₹)13.0016.0013.008.505.005.004.00
Book value per share (₹)423.39397.46346.49305.25279.05247.10215.85

Investments & Acquisitions by Cipla

Cipla has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include Avenue Therapeutics, Cipla Biotec and Cipla Medpro.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Inzpera
Develops health products for nutritional balance and wellness promotion.
inzpera.comMumbai, India2016Nov 2025$12.48M
Endura Supplements
Endura Supplements is engaged in providing nutritional and wellness products.
endurasupplements.comSolan, India2010Jul 2022$9.83M
Avenue Therapeutics
Formulation of tramadol HCI for the treatment of moderate to moderately severe post-operative pain.
avenuetx.comNew York, United States2015Nov 2018$215M
Mirren
Natural gas assets are developed alongside innovative pipeline solutions.
mirren.co.zaJohannesburg, South Africa1983Jul 2018$33.39M
Exelan Pharma
Biscuits, wafers, noodles, coffee, and other snacks are manufactured.
exelanpharma.comLawrenceville, United States2011Sep 2015••••
InvaGen
Generic pharmaceuticals are developed and marketed across therapeutic areas.
invagen.comHauppauge, United States2003Sep 2015••••
Cipla Biotec
Monoclonal antibodies (mAb) to treat cancers & Wet Age-Related Macular Degeneration and Peptide hormone to treat diabetes.
ciplabiotec.comSalcete, India2008Jun 2014••••
Cipla Medpro South Africa
Pharmaceutical drugs are manufactured by Cipla Medpro South Africa.
ciplamedsa.co.zaCape Town, South Africa1970Jul 2013$453.13M
Cipla Medpro
Generic pharmaceuticals are manufactured and marketed for South African customers.
cipla.co.zaCape Town, South Africa1998Feb 2013$512M
Premium access

Complete acquisition details for Cipla

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Cipla

11 dated milestones of Cipla across 90 years, from founding to its latest funding, stage changes and deals.

  1. Founded Cipla is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Acquisition Acquires Cipla Medpro.
  4. Acquisition Acquires Cipla Medpro South Africa.
  5. Acquisition Acquires Cipla Biotec.
  6. Acquisition Acquires InvaGen.
  7. Acquisition Acquires Exelan Pharma.
  8. Acquisition Acquires Mirren.
  9. Acquisition Acquires Avenue Therapeutics.
  10. Acquisition Acquires Endura Supplements.
  11. Acquisition Acquires Inzpera.

Web traffic of Cipla

The website of Cipla (cipla.com) receives about 200.9K visits a month and ranks #203,362 among all websites worldwide, #6,599 in Health.

  • Monthly visits
    200.9K

    ▲ 3.5% vs previous month

  • Unique visitors
    84.6K

    per month

  • Global rank
    #203,362

    among all websites

  • Category rank
    #6,599

    Health · Health

Similar websites

Websites whose visitors overlap most with Cipla. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Sun Pharma
sunpharma.com
100%
216K#177,160View details
Dr. Reddy's Laboratories
drreddys.com
86%
118.8K#308,607View details
Ranbaxy Laboratories
ranbaxy.com
82%
View details
Aurobindo Pharma
aurobindo.com
67%
24.4K#1,029,164View details
Tata 1mg
1mg.com
66%
44.9M#1,062View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Cipla

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Cipla (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 72.52 M1,115
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cipla

Cipla: HSBC on Cipla Maintains Hold, Target Price Rs 1,400; Q2 performance was lacklustre, with FY27 EBITDA margin guidance of 18.5–20% and the US$1bn annualised US-sales exit-rate target unchanged. Execution of key US launches, particularly inhalers, remains critical to meeting guidance.
Exchange Update • 16 days ago
Cipla: CLSA on Cipla Maintains Outperform, Target Price Rs 1,600; Q2 revenue marginally missed estimates despite record India performance led by Yurpeak, while margins improved QoQ on a better product mix. Cipla reiterated its US$1bn FY27 US-sales exit-rate target, supported by three new launches and growth in generic Ventolin and Advair; it plans to file 45–50 complex products over three years.
Exchange Update • 16 days ago
CIPLA: Q2 CONS NET PROFIT 8.8B RUPEES VS 13.5B (YOY); EST 9.5B
Exchange Update • 17 days ago
CIPLA: Q2 REVENUE 74B RUPEES VS 75.9B (YOY); EST 74.98B
Exchange Update • 17 days ago
CIPLA: Q2 EBITDA 13.87B RUPEES VS 18.94B (YOY), EST 13.71B; Q2 EBITDA MARGIN 18.74% VS 24.97% (YOY), EST 18.3%
Exchange Update • 17 days ago
Cipla: Co's Focus On Growth In North America Through New Product Launches
Exchange Update • 17 days ago
Cipla: Co Plans To Reach $1 Billion Revenue In North America By FY27
Exchange Update • 17 days ago
Cipla: Co Maintain 18.5 - 20% EBITDA Margin Guidance For FY27
Exchange Update • 17 days ago
Cipla: Respiratory Drug Ventolin To Contribute Growth In U.S In Coming Quarters
Exchange Update • 17 days ago
Maharashtra FDA Cancels Cipla Unit’s Drug Sale Licence Over Alleged Violations - Newspaper
Exchange Update • 1 month ago
Premium access

Complete news archive for Cipla

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Articles about Cipla on our blog

Frequently Asked Questions about Cipla

Cipla was founded in 1935.

Cipla is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Umang Vohra is the CEO of Cipla, as recorded in our data.

Cipla has 2,319 employees.

The primary company behind Cipla, Cipla Limited, reported revenue of ₹20,103 Cr for FY 2026, up 5% year on year.

Founded in 1935 and headquartered in Mumbai, India, Cipla operates in the pharmaceutical sector. Active pharmaceutical ingredients, generic drugs, and formulation development services are produced. A broad portfolio covers therapeutic areas including allergy, cardiology, dermatology, diabetology, gastroenterology, HIV-AIDS, oncology, respiratory, and urology. Leadership is provided by CEO and Managing Director Umang Vohra. Operations focus on global distribution of these products.

Cipla offers Potatoes and Grain Marketing.

Yes, Cipla is publicly traded on NSE under the ticker symbol CIPLA.

Cipla has made 9 acquisitions, including Avenue Therapeutics, Cipla Biotec, and Cipla Medpro.

Cipla operates through Cipla Limited.

The legal entities of Cipla currently have 12 directors, including Prathivadibhayankara Rajagopalan Ramesh, Mandar Purushottam Vaidya, Yusuf Khwaja Hamied and others.

The website of Cipla receives about 201 thousand visits a month and ranks #203,362 among all websites worldwide.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available